Objective: Ischemia-reperfusion (IR) is a limb-and life-threatening complication of acute limb ischemia and musculoskeletal trauma. Carbon monoxide-releasing molecules (CORMs) have recently been shown to protect microvascular perfusion and to reduce inflammation and injury in various ischemic animal models. The purpose of this study was to examine the effects of water-soluble CORM-3 on the extent of IR-induced muscle injury.
Skeletal muscle ischemia, particularly in the lower extremities, is a common clinical problem occurring as a consequence of acute arterial thromboembolism or trauma. [1] [2] [3] Restoration of blood flow after ischemia leads to a significant ischemia-reperfusion (IR) injury, characterized by edema, microvascular perfusion deficits, muscle injury, and loss of muscle function. 3, 4 Revascularization procedures may be technically successful, but IR-induced microvascular dysfunction (the no-reflow phenomenon) is characteristic of prolonged ischemic intervals and may lead to overall failure of a limb salvage attempt.
It is generally agreed that IR injury is associated with the initiation of local (eg, limb swelling) and systemic response, thus contributing to multiple organ injury and dysfunction. 1 Whereas the complications of IR injury have been recognized for several decades, the complex pathophysiologic mechanism of IR and thus potential therapeutic interventions are still poorly understood, requiring further investigation.
The contribution of inflammation to the pathophysiologic mechanism of IR is being increasingly recognized; studies from our group 5, 6 and others 7, 8 have broadly implicated leukocytes (neutrophils in particular) as playing a primary role in both microvascular and parenchymal injury during IR. The IR-induced tissue injury within skeletal muscle has been shown to progress further during reperfusion 4 and is closely associated with an increase in the number of activated leukocytes. 5 Few therapeutic options have been shown to be effective in reducing or preventing IR injury. Carbon monoxide (CO), a byproduct of heme oxygenase activity, can offer both protection to microvascular perfusion and antiinflammatory benefit during systemic inflammation. 9, 10 Although the exogenous administration of inhaled CO appears beneficial in systemic inflammatory response syndrome, 10 it can also result in increased carboxyhemoglobin (COHb) levels, thus presenting a potential danger to the patients. Transitional metal carbonyls, CO-releasing molecules (CORMs), have recently been used to deliver CO without significantly altering COHb. 11 Consequently, CORMs have received increased attention for a potential pharmaceutical application. 12, 13 CORMs-derived CO has been found to produce vasorelaxant effects, decreasing myocardial IR damage and reducing inflammatory response in various animal models. [14] [15] [16] The purpose of this study was to investigate the effects of CO, liberated from a water-soluble CO donor, CO-releasing molecule 3 (CORM-3), on the temporal progression of microvascular dysfunction and tissue injury after hind limb IR. The ultimate goal is the development of a pharmacologic therapy to mitigate IR-associated skeletal muscle tissue damage, thus reducing the morbidity in patients.
METHODS
Animal preparation. The experimental protocol was approved by the Council on Animal Care of the University of Western Ontario and has been previously described in detail. 4 Briefly, male Wistar rats (body weight, 180-250 g)
were anesthetized by inhalational isoflurane (5% induction, 2% maintenance) in 1:1 oxygen-nitrogen mixture. The left carotid artery was cannulated to allow the continuous monitoring of systemic blood pressure, fluid administration, and blood sampling. This model of hind limb skeletal muscle ischemia has been described previously. 4 Briefly, acute ischemia was induced by application of tourniquet (No. 4 silk suture; Johnson & Johnson, New Brunswick, NJ) just above the greater trochanter on the rat right hind limb, resulting in a no-flow ischemia (confirmed by intravital video microscopy), and maintained for 2 hours. Reperfusion was initiated by tourniquet release, followed by 90 minutes of intravital video microscopy.
CORM-3.
A water-soluble CORM-3 (tricarbonylchloroglycinate-ruthenium(II), [Ru(CO) 3 Cl-glycinate]; molecular weight, 295 gmol À1 ), an equimolar CO donor, was synthesized by us in accordance with a previously published method. 17 CORM-3 (10 mg/mL stock solution)
was prepared fresh by dissolving it in isotonic saline just before injection (CO release from CORM-3 was confirmed spectrophotometrically by conversion of deoxymyoglobin to carbonmonoxymyoglobin; data not shown). Inactive CORM-3 (iCORM-3) served as a control and was generated by dissolving CORM-3 in saline 72 hours before the experiment, thus releasing all CO from the solution (lack of CO release was confirmed by myoglobin-binding assay).
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Experimental groups. Rats were randomly assigned to one of three experimental groups: sham (n ¼ 4), IR þ CORM-3 (n ¼ 5), and IR þ iCORM-3 (n ¼ 5). CORM-3 or its inactive form (iCORM-3) was administered to animals undergoing IR just before reperfusion at the dose of 10 mg/kg (34 mmol/kg) intraperitoneally. Sham animals underwent all the same procedures as IR groups did (including iCORM-3 injection), but the tourniquet was not tightened.
Intravital video microscopy. The extensor digitorum longus (EDL) muscle was dissected to the level of its distal tendon, which was tied with a suture and cut from its bone insertion. The animal was transferred onto the stage of an inverted microscope (Nikon, Tokyo, Japan); the EDL was reflected into a continuously monitored, temperature-controlled saline bath, maintained at 32 with 20Â and 40Â objectives, respectively, in three adjacent fields of view containing at least one or two microvascular units. The same three fields of view were followed in 15-minute intervals for a total of 90 minutes of reperfusion. Fluorescence microscopy was used to visualize the BB and EB from the same fields of view that had been selected for the measurement of capillary perfusion. At the conclusion of the experiment, a final blood sample was drawn from each animal for the measurement of COHb level; rats were then euthanized by an overdose of anesthetic agent.
Offline video analysis. As previously described, 4 capillary perfusion was assessed by counting the number of continuously perfused capillaries (CPCs), intermittently perfused capillaries, and nonperfused capillaries (NPCs) that crossed three parallel lines drawn perpendicular to the capillary axis on the video monitor and was expressed as percentage of total capillaries. Tissue injury was assessed by counting the number of EB-and BB-labeled nuclei and expressed as EB/BB ratio. Leukocyte activation was assessed by counting the numbers of rolling and adherent leukocytes in postcapillary venules and expressed per 1000 mm 2 . Venular area was measured using ImageJ (National Institutes of Health, Bethesda, Md). A leukocyte was considered adherent if it remained stationary for at least 30 seconds, and a cell was considered rolling if it remained in contact with the wall of the vessel during its movement. COHb measurement. Systemic COHb level (%) was assessed in arterial blood samples collected at 90 minutes after CORM-3/iCORM-3 injection by CO oximetry (GEM Premier 4000 Blood Gas Analyzer at London Health Sciences Centre Core Laboratories).
Serum tumor necrosis factor-a (TNF-a) measurements. TNF-a levels were measured from arterial blood samples drawn at eight time points: baseline; 2 hours into ischemia, just before reperfusion and CORM-3 (or iCORM-3) injection; and every 15 minutes during reperfusion (for the total of 90 minutes of reperfusion time). Care was taken to ensure the withdrawal of only a minimal amount of blood (0.1 mL), immediately replaced with sterile normal saline, at each time point, to avoid any effects on systemic blood pressure. TNF-a was assessed using enzyme-linked immunosorbent assay (Pierce Biotechnology, Division of Thermo Scientific, Rockford, Ill) according to the manufacturer's instructions. The TNF-a enzyme-linked immunosorbent assay was sensitive to <5 pg/mL. Statistical analysis. All parameters were expressed as mean 6 standard error of the mean and analyzed using repeated-measures analysis of variance (GraphPad Prism, version 5c; GraphPad Software Inc, San Diego, Calif), with Bonferroni tests used as post hoc analysis where appropriate. Sample size calculation was performed using StatMate (GraphPad Software Inc), with power set at 85%. P < .05 was considered statistically significant.
RESULTS
Hind limb ischemia did not produce any significant changes to mean arterial blood pressure, which was maintained within normal physiologic parameters of 80 to 100 mm Hg for the duration of the experiment. Administration of CORM-3 or iCORM-3 did not result in any changes to systemic blood pressure (data not shown) or COHb (1.6% 6 0.1% in both IR þ iCORM-3 and IR þ CORM-3 groups vs 1.5% 6 0.2% in sham).
Capillary perfusion and microvascular dysfunction.
Hind limb ischemia resulted in a significant decrease in CPCs in both CORM-3 and iCORM-3 groups at the commencement of reperfusion (37% 6 4% CPCs in iCORM-3, 44% 6 2% CPCs in CORM-3 groups vs 77% 6 4% CPCs in sham [P < .001]; Fig 1) . Within 15 minutes of the onset of reperfusion, there was a significant reduction in CPCs (25% 6 4% vs 76% 6 4% in sham; P < .001) and an increase in NPCs in iCORM-3 group (48% 6 3% vs 13% 6 2% in sham; P < .05); this trend of temporal decrease of CPCs continued for the entire duration of the experiment. However, in CORM-3 group, there was a significant increase in CPCs within 15 minutes of reperfusion (50% 6 5% vs 25% 6 4% in iCORM-3 group; P < .05). The CPCs continued to increase (Fig 1) while NPCs continued to decrease (Fig 2) for the duration of observation (58% 6 5% CPCs in CORM-3 vs 21% 6 2% in iCORM-3, and 21% 6 3% NPCs in CORM-3 vs 52% 6 8% in iCORM-3 at 90 minutes of reperfusion; P < .001). There were no significant changes in intermittently perfused capillaries between CORM-3 and iCORM-3 groups, although the levels were significantly higher compared with sham (Fig 3) . P < .001; Fig 5) . By the conclusion of the experiment, after iCORM-3 group; P < .05; Fig 6) . The effect of CORM-3 was apparent for the duration of the observation period Systemic TNF-a. Levels of systemic TNF-a remained statistically unchanged during the ischemic period in both CORM-3 and iCORM-3 groups (baseline of 432.3 6 105.3 pg/mL). Limb IR led to a spike in systemic TNF-a levels, reaching its maximum at 15 minutes of reperfusion (1565.7 6 449.5 pg/mL; Fig 7) . TNF-a levels returned to preischemic levels after 60 minutes of reperfusion. CORM-3 completely abolished the IR-associated rise in TNF-a; this became apparent within 15 minutes of injection (15.7 6 7.8 pg/mL) and continued for the duration of observation (Fig 7) .
DISCUSSION
Reperfusion injury poses a challenging clinical problem associated with significant morbidity and mortality. 3, [18] [19] [20] [21] This holds true in all revascularization procedures, whether they are carried out on an emergency basis, because of acute arterial thromboembolism or trauma, or on an elective basis, and it may significantly contribute to the failure of an operation. To date, treatment of ischemic and IR-induced conditions is limited and requires the development of more effective approaches and strategies.
In this study, we demonstrated for the first time an improvement in skeletal muscle microvascular perfusion, inhibition of inflammation, and attenuation of cellular injury by the systemic administration of CORM-3 in an experimental model of limb IR.
CO, a gaseous signaling molecule produced endogenously as a byproduct of heme degradation, has been shown to exhibit vasodilatory, antiapoptotic, and anti-inflammatory effects in many animal models. 12 Nevertheless, therapeutic administration of CO by inhalation is hampered by the production of COHb, limiting its clinical applicability. It has been shown previously that despite some beneficial effects, CO inhalation in (n ¼ 5) completely blocked the TNF-a spike evident by 15 minutes of reperfusion (*P < .05 from baseline,
humans (500 ppm for 1 hour) increased COHb in the range of 1.2% to 7%. 22 Similar findings were obtained from in vivo animal models, in which COHb levels of 5% to 6% were obtained, 10 some even reaching 15% to 25%, 23 depending on the experimental conditions.
Transitional metal carbonyls, CORMs, have recently been developed as a means of CO delivery in biologic systems, with minimal or no effect on COHb formation, 16, 17, 24, 25 making them potential candidates for therapeutic agents. Several studies have demonstrated CORMmediated protection against IR-induced injury to the heart, 17,25 kidney, 26 liver, 27 and intestine. 24 However, the role of CORM-derived CO on modulation of inflammation in IR-challenged skeletal muscle had not yet been investigated. IR injury is composed of a complex chain of events, leading to upregulation of the proinflammatory phenotype and subsequent inflammatory interactions between the vascular endothelial cells, cells of the interstitium (eg, fibroblasts, myofibroblasts, smooth muscle cells), and circulating cells (leukocytes). In turn, this leads to impaired vascular cell integrity, increased vascular permeability, and formation of edema. The temporal changes in microvascular perfusion (ie, the no-reflow phenomenon) appear to be caused not just by passive alterations in external pressure from edema but also by spastic changes in the vasculature, leading to vasoconstriction. 28 The NPCs potentiate further damage by contributing to the endothelial cell swelling, capillary narrowing due to edema, and increased intravascular blood viscosity from hemoconcentration. 29 In our study, IR resulted in a significant no-reflow phenomenon in both CORM-3 and iCORM-3 groups at the commencement of reperfusion (Fig 1) . Administration of CORM-3, however, contributed protection to the microvascular perfusion, as evidenced by the continuous trend toward progressive perfusion improvement in CORM-3-treated animals. Whereas it is unlikely that CORM-3-derived CO would have directly prevented IR-induced formation of edema, the potent vasodilatory properties of CO (mediated by soluble guanylate cyclase) could explain the diminished spasticity of the microvasculature, resulting in the decreased severity of the no-reflow phenomenon.
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The parenchymal damage seen in IR appears to result from both the direct microvascular dysfunction due to hypoxia and subsequent inflammation. 4, 30 Oxygen deprivation depletes adenosine triphosphate, leading to tissue necrosis. 31 In our experiments, limb IR resulted in a significant progressive increase in tissue injury; the levels of injury were virtually unchanged from the baseline in the presence of CORM-3 treatment, suggesting a substantial protective role of exogenously applied CO. Several studies have shown that CORM-3-derived CO is capable of reducing the levels of oxidative stress in vascular endothelial cells, 32 cardiac myocytes, 33 and inflammatory cells (polymorphonuclear [PMN] cells, macrophages). 15 Our current findings demonstrate almost complete abolishment of the reperfusion injury and its progressive temporal escalation after CORM-3 treatment and thus lend support to the concept of antioxidant properties of CORM-3-derived CO; although it may not act as a free radical scavenger itself, CORM-3 may have the ability to suppress the oxidative stress in endothelial cells indirectly, thus minimizing the extent of endothelial cell injury. In fact, studies indicate that CORM-3 is a potent inhibitor of myeloperoxidase activity (a PMN cell-derived enzyme responsible for the production of one of the most potent oxidizers in biologic systems, hypochlorous acid) 34 and may suppress or inhibit leukocyte (ie, PMN cell)-induced oxidative damage to the vascular endothelium. Leukocyte activation has long been recognized as one of the driving forces in IR injury. 5, 35 The production of acute phase inflammatory cytokines and chemokines (eg, TNF-a) leads to PMN cell activation and recruitment into inflamed tissues. 30 In turn, activated leukocytes produce reactive oxygen species that act as signaling molecules in initiating and amplifying inflammatory cell activation. In addition, through direct oxidation and peroxidation of lipids and proteins within cellular membrane, reactive oxygen species impair membrane function and overall cell viability. 36 If not checked, this further perpetuates cell activation, resulting in increased levels of circulating proinflammatory cytokines and subsequent development of systemic inflammation and remote organ injury. 37 In our study, we observed a "classic" spike in the levels of circulating TNF-a, one of the most potent proinflammatory cytokines, within 15 to 30 minutes of commencing reperfusion. This was accompanied by a continuous, progressive activation of leukocytes within the skeletal muscle microvasculature with respect to increased leukocyte recruitment (ie, rolling and adhesion). Interestingly, CORM-3 completely prevented the reperfusion-induced leukocyte activation and adhesive interactions with microvascular endothelium, the phenomenon closely related to CORM-3-dependent suppression of TNF-a levels in circulation. These findings further support previous studies demonstrating anti-inflammatory properties of CORM-3. 38 Whereas the exact mechanisms of CORM-3-induced anti-inflammatory effects are, at the moment, unknown, it is plausible to assume that the beneficial effects of the systemically administered CORM-3 may be related to the ability of CO to act simultaneously on multiple cellular and molecular targets. Our current findings are in agreement with many previous studies demonstrating CORM-dependent suppression of both vascular and leukocyte proadhesive phenotypes and subsequent reduction or prevention of leukocyte-endothelium adhesive interaction. 14, 15, 32, 39, 40 It has been shown that CORM-3 may directly or indirectly interfere with the expression of immunoglobulin superfamily adhesion molecules (such as intercellular adhesion molecule 1, vascular cell adhesion molecule 1) on endothelial cells or selectins (Eselectin, P-selectin, or L-selectin) on leukocytes. As leukocytes are a significant contributor to tissue damage, any inhibition of leukocyte activation or reduced recruitment of these cells to the tissues would reduce the magnitude of leukocyte-induced tissue injury and dysfunction. 34 Whether CORM-3 preferentially interferes with the inflammatory activation of leukocyte or vascular endothelial cell (or both) in the model of limb IR employed in this study remains to be determined.
Whereas the results of our study are novel and look promising, the study was not without limitations. First, we used only a single concentration of CORM-3 and a single route of administration (ie, intraperitoneal). Different dosage, frequency, and alternative routes of CORM-3 administration (eg, intravenous) may provide different dynamics of CORM-3-dependent protection. Second, despite the fact that CORMs (eg, CORM-3) used at micromolar concentrations show no cytotoxic effects in cultured vascular endothelial cells and PMN cells (data not shown), the potential toxicity of various concentrations of CORM-3 in vivo is yet to be determined. Few data exist on the safety of systemic CORM-3 administration in large animals, although preclinical studies employing nonhuman primates suggest that there are few side effects associated with both single and repeated injections. 39 
CONCLUSIONS
This is the first study demonstrating the beneficial effects of CORM-3-derived CO as a preventive measure to avoid or to mitigate the progression of reperfusioninduced microvascular dysfunction in the skeletal muscle. Whereas the exact mechanisms of CORM-3 protective action remain to be determined, the obtained data strongly indicate a potential therapeutic application of CORMs in patients undergoing prolonged ischemia, in whom reperfusion injury might be of serious concern. 
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